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Background: Entamoeba histolytica is an intestinal protozoan parasite that causes amoebiasis in humans, affecting
up to 50 million people worldwide each year and causing 40,000 to 100,000 deaths annually. EhCP112 is a cysteine
proteinase of E. histolytica able to disrupt cell monolayers and digest extracellular matrix proteins, it is secreted by
trophozoites and it can be active in a wide range of temperature and pH. These characteristics have encouraged
the use of EhCP112 in the design and production of possible vaccines against amoebiasis, obtaining promising
results. Nevertheless, we have no conclusive information about the role of EhCP112 in the E. histolytica
pathogenesis.
Methods: A set of three specific siRNA sequences were used to silence the Ehcp112 gene via the soaking system.
Silencing was evaluated by Western blot using an antibody against the EhCP112 recombinant protein. Finally, we
analyzed the protease activity, the phagocytosis rate and the ability to destroy MDCK cells of the EhCP112-silenced
trophozoites.
Results: The highest silencing effect on EhCP112 was detected at 16 h of treatment; time enough to perform the
in vitro virulence assays, which showed that EhCP112 silencing produces a significant reduction in cytolysis and
phagocytosis of target cells, indicating the participation of this proteinase in these events.
Conclusions: EhCP112 is involved in the in vitro virulence of E. histolytica.
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Entamoeba histolytica is the intestinal protozoan parasite
that causes amoebic colitis and amoebic liver abscesses in
humans [1], affecting up to 50 million people worldwide
each year and causing 40,000 to 100,000 deaths annually
[2]. The cytopathogenic mechanism of this parasite
consists of three main steps: adherence, cytolysis, and
phagocytosis [3] and several molecules, including cyst-
eine proteinases (CPs), participate in these events [4].
CPs have been identified as crucial virulence factors
of protozoa parasites because they are associated to
cytoadherence, haemolysis, cytotoxicity, degradation of
extracellular matrix components, evasion of the im-
mune response and nutrient acquisition [5-10]. The* Correspondence: marodri@cinvestav.mx
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distribution, and reproduction in any mediumcharacterization of CP genes and their products have con-
firmed their relevance in invasion and colonization of host
tissues [11-20]. As in other parasites, CPs play an import-
ant role in the pathogenicity of E. histolytica [21]. The
genome of this parasite contains around fifty genes encod-
ing CPs, although only few of them are expressed at sig-
nificant levels in trophozoites grown in culture media
[22,23]. Those CPs not expressed in vitro are thought to
play a role in infection of the human host, invasion
and destruction of host tissue and completion of the
parasite life cycle [21].
EhCPADH is a protein complex of E. histolytica formed
by the EhCP112 cysteine proteinase and the EhADH112
adhesin [24]. This complex is located in cytoplasmic vesi-
cles and plasma membrane of trophozoites and is dimin-
ished in adherence- and virulence-deficient mutants [25].
EhCP112 contains a putative transmembranal domain and
a RGD sequence for interaction with integrins [24]. Thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 siRNA sequences
siRNA 1 Target sequence: 5′-AATCAAAAGACTCAAAGCATT-3′
Sense strand: 5′-UCAAAAGACUCAAAGCAUUUU-3′
Antisense strand: 5′-AAUGCUUUGAGUCUUUUGAUU-3′
siRNA 2 Target sequence: 5′-AATTGCTGTAAAATCCTTTTC-3′
Sense strand: 5′-UUGCUGUAAAAUCCUUUUCUU-3′
Antisense strand: 5′-GAAAAGGAUUUUACAGCAAUU-3′
siRNA 3 Target sequence: 5′-AAATATTTGTAGTTCATGTGT-3′
Sense strand: 5′-AUAUUUGUAGUUCAUGUGUUU-3′
Antisense strand: 5′-ACACAUGAACUACAAAUAUUU-3′
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monolayers, digests extracellular matrix proteins and is
active in a wide range of temperature and pH [26,27]. The
results obtained with the recombinant protein suggest that
EhCP112 could be involved in the pathogenic mechanism
of this parasite; however, the relevance of EhCP112 in the
virulence of E. histolytica has not been proved directly.
Here, we found that RNAi-mediated downregulation
of EhCP112 in E. histolytica trophozoites leads to a re-
duction of the in vitro virulence of the parasite.
Methods
Entamoeba histolytica cultures
Trophozoites of clone A [28], strain HM1: IMSS, were
axenically cultured in TYI-S-33 medium and harvested
during the logarithmic growth phase as previously de-
scribed [29].
Expression and purification of the recombinant EhCP112
protein
An Ehcp112 gene fragment (1278 bp), which encodes a
polypeptide containing the pro-peptide and the mature en-
zyme, cloned in the expression vector pTrcHIs C [26] was
used to transform bacteria E. coli, strain BL21 (pLys E).
These bacteria were incubated with 1 mM of Isopropyl
β-D-1-thiogalactopyranoside (IPTG) for 3 h at 37°C
[30] to induce the production of the recombinant
protein. Then, the EhCP112 recombinant protein
(rEhCP112), containing a poly-histidine tag, was puri-
fied through Ni2+-affinity columns (Qiagen, USA) fol-
lowing the manufacturer’s protocol.
Antibody generation
To obtain antibodies against rEhCP112, 100 μg of the
recombinant protein was subcutaneously inoculated four
times at intervals of 15 days on New Zealand rabbits.
The first immunization was performed in the presence
of complete Freund’s adjuvant (Sigma-Aldrich), and add-
itional immunizations were carried out in the presence
of incomplete Freund’s adjuvant (Sigma-Aldrich). The
experimental protocol was approved by the institutional
committee for animal care and provided all technical
specifications for the production, care and use of labora-
tory animals (NOM-062-ZOO-1999).
siRNA design
The complete Ehcp112 mRNA sequence (GenBank:
AF127375.2) was analyzed by the online program Target
finder [31] to obtain potential small interference RNA
(siRNA) sequences. Then, the multiple hypothetic se-
quences acquired were evaluated by nucleotide BLAST
[32], and by the multiple sequence alignment ClustalW
[33], comparing all the sequences reported in the
Entamoeba genome database Pathema [34], includingall E. histolytica CPs. A set of three specific siRNA oligo-
nucleotide sequences for Ehcp112 were chosen (Table 1)
and they were sent to their synthesis (Ambion). As a nega-
tive control, an additional set of scrambled sense and anti-
sense primers with a non-related sequence (NRS) were
synthesized.
siRNA preparation
All primers were diluted to 1 μg/μl in TE (10 mM Tris–
HCl, 1 mM EDTA) and then, respective sense and anti-
sense oligonucleotides were hybridized using the 1X
DNA Annealing Solution (Ambion) incubating at 90°C
for 3 min and then at 37°C for 1 h.
Soaking of E. histolytica trophozoites with siRNA
Trophozoites (1 × 106) freshly collected from 90% con-
fluent cultures were inoculated in 25 ml culture plastic
flasks (Corning) containing TYI-S-33 medium and incu-
bated at 37°C during 24 h. Then the annealed siRNAs at
25, 50 and 100 μg/ml were added to the cultures and in-
cubated at 37°C for 16, 24, and 36 h. To verify the
siRNA entry to trophozoites by this soaking method, 75
pmol of a fluorescein-labeled negative control siRNA
(Ambion) were added to 1 × 106 trophozoites during 2, 5
and 16 h and internalization of the labeled-siRNA was
analyzed by confocal microscopy. To determine the ef-
fect of the EhCP112 silencing on growth, the number of
trophozoites and its viability was analyzed by trypan blue
staining each 12 h after soaking with siRNA.
Western blot assays
Total extracts from E. histolytica were separated by 10%
SDS–PAGE and transferred to nitrocellulose membranes.
Then, membranes were incubated with antibodies
against rEhCP112 (1:10,000), followed by incubation
with a mouse anti-rabbit IgG secondary antibody conju-
gated to horseradish peroxidase (Invitrogen) (1:10,000).
Finally, the antibody detection was developed by incu-
bation with 3,3′-diaminobenzidine tetrahydrochloride
(Sigma-Aldrich) and H2O2. As internal control, the same
membranes were revealed with anti-actin antibodies
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antibodies were analyzed by densitometry and data
were normalized with those obtained from bands rec-
ognized by the anti-actin antibodies.
Protease activity
To analyze the protease activity, trophozoites were
washed twice with phosphate-buffered saline (PBS) and
suspended at concentration of 107/ml in PBS. The cellu-
lar pellets were lysed by five freeze-thaw cycles in liquid
N2 and 10 μl of a 1:1000 dilution were mixed with 10 μl
of 2× sample buffer without 2-mercaptoethanol and
electrophoresed in 10% SDS-PAGE copolymerized with
0.1% gelatin. After electrophoresis, gels were incubated
in 2.5% Triton ×-100 for 1 h at room temperature. CPs
were activated by incubation in buffer activation (Tris–
HCl 0.1 M pH 6.8, CaCl2 10 mM and 0.02% 2-
mercaptoethanol) for 12–16 h at 37°C. Gels were stained
with 0.25% Coomassie blue R-250 and clear bands were
indicative of proteolytic activity.
Cytotoxic and cytophatic assays
MDCK (Madin-Darby canine kidney) monolayers (1 ×
105 cells) grown in 24-well plates (Costar) were incu-
bated with 1 × 105 trophozoites (cytopathic assays) or
with total extracts from 1 × 106 trophozoites (cytotoxic
assays) in the presence of 0.02% of 2-mercaptoethanol
during 2 h at 37°C. After this time, trophozoites or their
extracts were eliminated and the remaining monolayers
were washed three times with PBS, fixed with 2.5% glu-
taraldehyde, and cellular destruction was evaluated as
previously described [35]. Briefly, cells were stained with
1% methylene blue, washed extensively and the dye cap-
tured by the rest of the monolayers was extracted with
0.1 N HCl and read in a spectrophotometer (Bechman
coulter DU800) at 660 nm. Results were reported as the
means ± standard deviation of three independent experi-
ments by duplicate.
Erythrophagocytosis
Erythrophagocytosis was measured using human red
blood cells (hRBCs) as previously described [36], with
some modifications. Fresh hRBCs (O Rh+) from healthy
donors were washed three times and resuspended in
serum-free amoeba culture medium. Then, trophozoites
were incubated with hRBCs at a ratio of 1:100 [28] at
37°C with slight agitation for 5 and 10 min, the standard
gap of time in the study of phagocytosis in E. histolytica
[28]. Then, the non-ingested erythrocytes were lysed by
incubation with distilled water for 10 min at room
temperature and trophozoites were washed three times
with PBS. Finally, samples were centrifuged at 360 × g
during 5 min and pellets of amoebae with internalized
hRBCs were resuspended in 1 ml of concentrated formicacid (J.T. Baker). Finally, the absorbance at 405 nm of
the samples was measured against a blank of formic acid
using a spectrophotometer (Beckman coulter DU800).
Data were normalized using the formula A405 of sample/
A405 of control trophozoites (NRS-treated) at 10 min of
phagocytosis. Results were reported as the means ±
standard deviation of the percentage of normalized
values of three independent experiments by duplicate.
Results and discussion
Generation of antibodies against EhCP112
EhCPADH is a protein complex formed by a CP
(EhCP112) and an adhesin (EhADH112) [24]. This com-
plex is located in cytoplasmic vesicles and plasma mem-
brane of trophozoites [24,25]. EhCP112 and EhADH112
have been independently characterized [24,26,27,37]. In
particular, the study and characterization of EhCP112
suggest that this protein could play an important role in
the virulence of E. histolytica [24,26,27,38], but there is
not a conclusive study about the role of EhCP112 in the
E. histolytica pathogenesis.
The RNAi technology has proved to be a strong tool
in molecular biology to study the functional analysis of cel-
lular genes [39,40] and also for the development of novel
therapeutic drugs to treat various incurable diseases
[41,42]. Indeed, this technology has been useful in the
study of E. histolytica [43-47]. Consequently, to confirm
that EhCP112 is involved in the E. histolytica pathogenesis,
we analyzed the in vitro virulence of EhCP112-silenced
trophozoites.
To analyze the EhCP112 silencing, first we obtained
specific antibodies against the recombinant EhCP112
(rEhCP112) [26]. Thus, the pTrcHIs-EhCP112 construc-
tion, encoding the pro-peptide and the mature enzyme
[26], was expressed in bacteria E. coli, strain BL21 (pLys E).
In SDS-PAGE of extracts of induced bacteria we observed
a slight enrichment of a 52-kDa protein (Figure 1A), the
expected molecular weight of rEhCP112 containing the
poly-histidine tag encoded by the vector. Then, through
Ni2+-NTA affinity columns we purified two polypeptides
of 52 and 43 kDa (Figure 1A). These polypeptides correlate
with the expected molecular weight of the pro-enzyme
(52 kDa) and the mature enzyme (43 kDa) variants of
EhCP112 containing the poly-histidine tag, suggesting that
rEhCP112 is an active enzyme [26].
In order to generate antibodies against EhCP112, New
Zealand rabbits were subcutaneously inoculated with
100 μg of the purified rEhCP112. Then, the antibodies
obtained were tested by Western blot. In these assays,
two bands were recognized in both the recombinant
protein and trophozoite extracts (Figure 1B, C). These
bands correspond to the expected molecular weight of
the pro-enzyme and the mature enzyme. No bands were
detected by the preimmune serum in trophozoite
Figure 1 Expression and purification of rEhCP112 and antibodies generation. (A) Expression and purification of rEhCP112. An Ehcp112 gene
fragment (encoding the pro-peptide and the mature enzyme) cloned in the pTrcHIs C expression vector was expressed in E. coli. Then, the
rEhCP112 was purified through Ni2+-affinity columns and analyzed by SDS-PAGE. Lane M, molecular weight markers; lane 1, uninduced bacteria
extracts; lane 2, bacteria extracts induced by IPTG; lane 3, purified proteins corresponding to the pro-peptide and mature enzyme (52 and
43 kDa). (B) Antibodies generation. The rEhCP112 was inoculated in rabbits. Then, serum was tested by Western blot assays using the rEhCP112
in a SDS-PAGE. (C) Western blot on E. histolytica extracts. To analyze the specificity of the antibody against rEhCP112 we performed Western blot
assays on total extracts of E. histolytica trophozoites; Lane 1, control using the preimmune serum; lane 2, antibody against rEhCP112.
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cific against EhCP112.
siRNA design
Once we had specific antibodies against EhCP112, we
designed the siRNA sequences using the complete
mRNA sequence of this CP (GenBank: AF127375.2) as
target. The online program Target finder [31] predicted
70 hypothetic target sequences. To determine the speci-
ficity of these potential target sites, we used the BLAST
tool of the Entamoeba genome database Pathema [34]
and the NCBI BLAST tool [32]. We eliminated from
consideration any target sequence with more than 10
contiguous base pairs of homology to other coding se-
quences in E. histolytica.
A set of three specific EhCP112 siRNA oligonucleotide
sequences were chosen (Table 1). These sequences are
located towards the 5′-end (siRNA 1), in the middle of
the mRNA sequence (siRNA 2), and towards the 3′end
(siRNA 3), they did not show significant homology to
other mRNAs encoding E. histolytica genes, included
other CPs. As a negative control, an additional set of
non-related sense and antisense primers were used.
Internalization of siRNA
Before performing the EhCP112-silencing, the entry of
siRNA into the trophozoites by the soaking method wasverified by confocal microscopy using a fluorescent-
labeled siRNA. In these experiments we observed that
since 5 min of incubation, the siRNA was bound to the
plasma membrane of the trophozoites, and a weak punctu-
ated label was detected inside the trophozoites (Figure 2A).
At 2 h of incubation the labeled-siRNA was detected
dispersed in the interior of the trophozoites (Figure 2B);
and at longer times (5 and 16 h), siRNA was observed as
fluorescent spots inside the trophozoites (Figure 2C, D),
but these spots were smaller after 16 h of incubation
(Figure 2D). These results showed that siRNAs are ef-
ficiently internalized into the trophozoites by the
soaking method.
EhCP112 silencing
In order to evaluate the silencing of EhCP112, we ana-
lyzed its expression by Western blot in trophozoites in-
cubated with the three siRNAs sequences at three
different concentrations (25, 50 and 100 μg/ml) for 16,
24 and 36 h. Each siRNA was tested separately and
mixed. In these assays we observed a decreased expres-
sion of EhCP112 in trophozoites treated for 16 and 24 h
with 50 μg/ml of the siRNA 1, corresponding to the 5′-
end of the gen, whereas the EhCP112 expression was
not affected by incubation with the siRNA control,
containing a non-related sequence (NRS) (Figure 3A).
As internal control we performed Western blot assays
Figure 2 Analysis of internalization of a fluorescein-labeled siRNA. Trophozoites were incubated at several times with a fluorescein-labeled
siRNA via soaking method. The entry to trophozoites was verified by confocal microscopy. (A) 5 minutes incubation; (B) 2 hours incubation;
(C) 5 hours incubation; (D) 16 hours incubation.
Figure 3 EhCP112 silencing. Trophozoites were incubated at different times with 50 μg/ml of the siRNA 1 via the soaking method and the
silencing of EhCP112 was analyzed by Western blot assays. (A) Western blot. Total extracts obtained from non-treated trophozoites (Ctl+),
trophozoites incubated with a double-strand RNA with non-related sequence (NRS) and trophozoites incubated with the siRNA 1 at different
times (16, 24 and 36 h) were analyzed by Western blot using the antibodies against rEhCP112. As internal control, membranes were also
incubated with an anti-actin antibody. (B) Relative expression of EhCP112. The bands recognized by antibodies were analyzed by densitometry.
The EhCP112 expression was normalized to actin expression and the value obtained in non-treated trophozoites was taken as 100% of relative
expression. Asterisks: P < 0.001.
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band with almost the same intensity in all samples
(Figure 3A). Densitometry of the bands detected,
showed that the EhCP112 expression decreased in 89
and 76%, after 16 and 24 h of incubation, respectively
(Figure 3B). However, after 36 h of incubation, the expres-
sion of EhCP112 decreased only 25% (Figure 3B), indicat-
ing that the silencing effect was reversible and dose
dependent. Some authors have been reported that in
eukaryotic cells, the siRNA in the RNAi process is de-
graded together with the mRNA, thus the process is notFigure 4 In vitro virulence of Ehcp112-silenced trophozoites. (A) Prote
with the siRNA 1 (EhCP112-silenced trophozoites) was analyzed in polyacry
trophozoites (Ctl+); lane 2, extracts from EhCP112-silenced trophozoites (SiR
sequence (NRS). Arrow indicates the 62-kDa band with minor proteolytic a
densitometry of the proteinase activity of the 62- and 49-kDa bands. (B) Cy
(SiRNA) and NRS-treated trophozoites (NRS) were incubated with MDCK m
(C) Cytopathic assays. EhCP112-silenced trophozoites (SiRNA) and NRS-trea
2 h. Then, the monolayer destruction was evaluated. (D) Erythrophagocyto
trophozoites (NRS) were incubated with human red blood cells during 5 an
value obtained with the NRS-treated trophozoites at 10 min of phagocytos
independent assays by duplicate and they are expressed as the means ± st
Asterisks: P < 0.001.continue [41,42]. On the other hand, the EhCP112 silen-
cing had no effect on the proliferation of the trophozoites
(data not shown), suggesting that this CP is not needed
for growth in culture medium.
The incubation of trophozoites with 100 μg/ml of
siRNA 1 not increased the EhCP112 silencing (data not
shown). In addition, siRNA 2 and siRNA 3 did not show
a significant effect in the EhCP112 expression. Conse-
quently, the incubation with the siRNA mixture did not in-
crease the EhCP112 silencing caused by siRNA 1 (data not
shown). Then, consecutive experiments were performedase activity. The protease activity of the trophozoites treated by 16 h
lamide-0.1% gelatin substrate gels. Lane 1, extracts from untreated
NA); lane 3, extracts from trophozoites treated with a non-related
ctivity in EhCP112-silenced trophozoites. Below is shown the
totoxic activity. Total extracts from EhCP112-silenced trophozoites
onolayers during 2 h. Then, the monolayer destruction was evaluated.
ted trophozoites (NRS) were incubated with MDCK monolayers during
sis assays. EhCP112-silenced trophozoites (SiRNA) and NRS-treated
d 10 min. Then, the ingestion of the target cells was evaluated and
is was arbitrary taken as 100% efficiency. Data were analyzed in three
andard deviation. Differences were evaluated by t-student test.
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siRNA 1, because in these conditions we observed the
most efficient effect on the EhCP112 silencing.
Effect of the EhCP112 silencing on the E. histolytica
in vitro virulence
Once the EhCP112 silencing was achieved, we deter-
mined its effect on the in vitro virulence of E. histolytica.
First, the protease activity of the silenced trophozoites
was analyzed in polyacrylamide-0.1% gelatin substrate
gels. The EhCP112-silenced trophozoites showed a 62-
kDa band with smaller proteinase activity to that of tro-
phozoites treated with the non-related sequence (NRS)
and untreated trophozoites (Figure 4A). Densitometry of
that band revealed a 55% minor activity in EhCP112-
silenced trophozoites with respect to controls, whereas
the 49-kDa band showed similar activity in all conditions
(Figure 4A). The 62-kDa band could correspond to the
active EhCP112 enzyme; its higher molecular weight is
probably due to the native electrophoretic conditions.
Nevertheless, these assays suggested that EhCP112 silen-
cing has a significant effect only in one band with prote-
ase activity in substrate gels.
In order to analyze the cytotoxic activity of total extracts
from EhCP112-silenced trophozoites, total amoeba ex-
tracts were incubated with MDCK monolayers during 2 h
and then the monolayer destruction was evaluated. Re-
sults showed that silenced trophozoites presented a sig-
nificantly reduction in the cytotoxic activity (25%) in
relation to the NRS-treated trophozoites (Figure 4B),
suggesting that EhCP112 has a relevant role in cytolysis.
In these assays we evaluated the monolayer cell destruc-
tion by total trophozoite extracts, where all the amoeba
cysteine proteinases have been released. Nevertheless,
there are few cysteine proteinases, including EhCP112,
reported to be secreted that could be involved in cytolysis
[26,48]. To analyze the role of EhCP112 in cell destruction
by trophozoites, we performed cytopathic assays using
EhCP112-silenced trophozoites on MDCK monolayers.
These experiments showed a significant decrease of
25% in cell destruction by the EhCP112-silenced tro-
phozoites in comparison with the cell destruction
performed by the NRS-treated trophozoites (Figure 4C),
eliciting the EhCP112 activity in cell destruction and tissue
invasion.
We also carried out erytrophagocytosis assays, because
phagocytosis is an event involved in the pathogenic
mechanism of E. histolytica [28]. Thus, we evaluated the
ingestion of human red blood cells (RBC) during 5 and
10 min by the EhCP112-silenced and NRS-treated tropho-
zoites. For these assays, the phagocytic value obtained
from NRS-treated trophozoites at 10 min of phagocytosis
was arbitrary taken as 100% efficiency. At 5 min of incuba-
tion, the difference between the EhCP112-silenced andthe NRS-treated trophozoites was 19%; silenced trophozo-
ites showed a phagocytosis efficiency of 44%, whereas
NRS-treated trophozoites displayed an efficiency of 63%
(Figure 4D). At 10 min of incubation, the difference be-
tween these populations was 34%; silenced trophozoites
showed 66% of phagocytosis efficiency (Figure 4D). These
results suggest that EhCP112 could be involved in the
phagocytic activity of E. histolytica.
Data obtained in this study support the hypothesis that
EhCP112 is involved in the pathogenicity of E. histolytica.
However, despite that expression of EhCP112 decreased
around 89% after incubation with siRNA, cell cytotoxicity,
cytopathic effect and erythrocyte phagocytosis between
siRNA and NRS treated trophozoites showed minor, but
significant, differences (25 to 34%). These results suggest
that other mechanisms might also contribute in these
processes.
On the other hand, it has been reported that the ex-
pression of the homologue of EhCP112 in E. invadens, a
related parasite of reptilians, is increased in the cyst
stage [49], suggesting that this CP could also participate
in development of the life cycle in Entamoeba sp. The
EhCP112 silencing could be useful to test this possibility;
unfortunately the in vitro encystation of E. histolytica is
not still available.
Conclusions
In this study we achieved the silencing of EhCP112 by
siRNA. The highest silencing effect was detected at 16 h of
treatment; time enough to perform the in vitro virulence
assays, which showed that EhCP112 silencing produces a
significant reduction in cytolysis and phagocytosis, indicat-
ing the participation of EhCP112 in these events. These re-
sults and those obtained with the EhCP112 recombinant
protein [26] support the use of EhCP112, in combination
with other virulence factors of E. histolytica, as a thera-
peutic target or a vaccine candidate.Abbreviations
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